Shin Nippon Biomedical Laboratories, Ltd.
8.15
EUR
+0.05
(+0.62%)
ISIN
JP3379950003
Return %
Stock
S&P 500
1Y
-5.78
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Ryoichi Nagata
- Full Time Employees
- 1,522
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 2438 Miyanoura-cho Tokyo Japan 891-1394
- IPO Date
- Mar 8, 2004
- Website
- snbl.co.jp
- Similar Companies
- Business
- Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japan-based contract research organization (CRO) providing comprehensive pharmaceutical development services, including non-clinical studies such as single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, toxicokinetic studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies; clinical services encompassing investigator brochure preparation support, clinical trial protocol creation support, investigational drug allocation, monitoring, quality management, data management, statistical analysis, comprehensive report creation support, electronic application support, regulatory affairs consulting, site management organization services, and clinical CRO services from Phase I to Phase IV; translational research focused on research and development of vaccines, therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines; as well as medipolis operations including geothermal power generation, hotel accommodations, wellbeing services, cleaning, clerical work, and welfare services. The company serves pharmaceutical companies, biotech ventures, universities, and research institutions primarily in Japan and internationally, with operations spanning the United States, China, Indonesia, Cambodia, and Europe for non-human primate breeding and testing facilities. Founded in September 1957 and headquartered in Kagoshima City, Japan, with additional key offices in Tokyo and facilities worldwide, SNBL maintains subsidiaries like SNBL U.S.A., Ltd., Inari Research Co., Ltd., Satsuma Pharmaceuticals (made a consolidated subsidiary in 2023 following its 2023 acquisition), and the joint venture SNBL PPD with Thermo Fisher Scientific. Recent developments include the establishment of a new research building at the Kagoshima headquarters in 2024 equipped for Microphysiological Systems (MPS); a business alliance and joint fund with SBI Holdings, Inc. announced in July 2024 and formalized in September 2024 to support early-stage startups in North America through investments in SNBL's U.S. incubation facility in Washington State; a joint research and development agreement with Cardio Intelligence Inc. for AI-based long-duration electrocardiogram analysis; and the affiliate Shin Nippon Science Tasso's certification of the TS Blood Collection Kit as a regulated medical device under Japan's Pharmaceutical and Medical Device Act.